单剂AMBITION方案对人类免疫缺陷病毒相关隐球菌脑膜炎在高收入国家的适用性如何
AMBITION-cm试验在东部和南部非洲开展,显示单剂高剂量(10 mg/kg)脂质体两性霉素B联合口服氟康唑和氟胞嘧啶,在治疗人类免疫缺陷病毒(HIV)相关隐球菌脑膜炎方面不劣于世界卫生组织(WHO)推荐的脱氧胆酸两性霉素B联合氟胞嘧啶7天方案,并已被纳入WHO治疗指南。作者认为该试验方案对高收入国家的HIV相关隐球菌脑膜炎治疗也有重要意义,论证其可能具有与当前推荐的14天脂质体两性霉素B方案相当的杀真菌活性、耐受性更好且不良反应更少,并带来显著的经济和实践益处,因此应作为治疗选择纳入高收入国家HIV相关隐球菌治疗的指南。
要点
- AMBITION-cm试验显示单剂高剂量(10 mg/kg)脂质体两性霉素B联合口服氟康唑和氟胞嘧啶不劣于WHO推荐的7天脱氧胆酸两性霉素B联合氟胞嘧啶方案。
- 该方案已被纳入WHO治疗指南,作者认为其可能对高收入国家的HIV相关隐球菌脑膜炎治疗有重要启示。
- 作者论证该方案可能具有与当前推荐的14天脂质体两性霉素B方案相当的杀真菌活性、耐受性更好且不良反应更少,并带来显著经济与实践益处。
核心结论
- 作者认为AMBITION-cm试验方案可能具有与当前推荐的14天脂质体两性霉素B方案相当的杀真菌活性、耐受性更好且不良反应更少,并带来显著经济与实践益处,因此应作为治疗选择纳入高收入国家HIV相关隐球菌治疗的指南。
研究设计与样本
- 本文为针对AMBITION-cm试验及其对高收入国家适用性的论述性文章,未报告系统检索范围与样本量。
主要发现
- AMBITION-cm试验在东部和南部非洲开展,显示单剂高剂量(10 mg/kg)脂质体两性霉素B联合口服氟康唑和氟胞嘧啶不劣于WHO推荐的脱氧胆酸两性霉素B联合氟胞嘧啶7天方案。
- 作者论证该试验方案可能具有与当前推荐的14天脂质体两性霉素B方案相当的杀真菌活性、耐受性更好且不良反应更少,并带来显著经济与实践益处。
关键数值与推荐
- AMBITION-cm试验方案:单剂高剂量(10 mg/kg)脂质体两性霉素B联合口服氟康唑和氟胞嘧啶。
- WHO推荐方案:脱氧胆酸两性霉素B联合氟胞嘧啶7天。
- 当前高收入国家推荐方案:14天脂质体两性霉素B方案。
临床怎么用
- 作者认为应将AMBITION-cm试验方案作为治疗选择纳入高收入国家HIV相关隐球菌治疗的指南。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The AmBisome Therapy Induction Optimization (AMBITION-cm) trial, conducted in eastern and southern Africa, showed that a single, high dose (10 mg/kg) of liposomal amphotericin B, given with an oral backbone of fluconazole and flucytosine, was noninferior to the World Health Organization (WHO)-recommended regimen of 7 days of amphotericin B deoxycholate plus flucytosine for treatment of human immunodeficiency virus (HIV)-associated cryptococcal meningitis and has been incorporated into WHO treatment guidelines. We believe that the trial also has important implications for the treatment of HIV-associated cryptococcal meningitis in high-income settings. We advance the arguments, supported by evidence where available, that the AMBITION-cm trial regimen is likely to be as fungicidal as the currently recommended 14-day liposomal amphotericin-based treatments, better tolerated with fewer adverse effects, and confer significant economic and practical benefits and, therefore, should be included as a treatment option in guidance for HIV-associated cryptococcal treatment in high-income settings.
引用
- Harrison TS, Lawrence DS, Mwandumba HC, et al. How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis to High-Income Settings? Clin Infect Dis. 2023. PMID: 36166405. doi:10.1093/cid/ciac792
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。